Heartseed loses Novo Nordisk backing for groundbreaking heart failure therapy
A promising cardiac treatment now stands alone. After Novo Nordisk's abrupt exit, Heartseed must navigate Phase 2 trials—and an uncertain future—without its pharma giant ally.